Skip to main content
. 2019 Jun 20;9:8836. doi: 10.1038/s41598-019-45237-5

Figure 4.

Figure 4

Quantification of UPR proteins in different glioblastoma cell lines non-treated and treated with Bortezomib using Orbitrap Fusion Lumos Tribrid Mass Spectrometer. Applying the optimized PRM assay, the expression level of the low abundancy UPR proteins at basal level and under treatment with 1 nM Bortezomib could be determined. The ratios between internal standard peptide and the endogenous peptide (light to heavy ratio) are presented. All the measurements were performed with three biological replicates.